Where We Showed EYE TELL at ASGH — Hong Kong

The energy at Asia Society for Global Health's 2026 summit in Hong Kong felt different from other conferences we'd attended. Walking through the registration hall on the first morning, we could sense it—a density of decision-makers, a real appetite for solutions that could scale across Asia's diverse healthcare systems. That appetite would define our three days there.

Arriving With Something Different

EYE TELL's booth sat in the innovation corridor, positioned alongside hardware-heavy diagnostic platforms and traditional telemedicine players. Our setup was deliberately minimal: a tablet, a smartphone, and a clear message. No special cameras. No proprietary devices. Just a 30-second pupil scan through a standard browser.

Within the first two hours, we understood why we'd drawn attention. One senior healthcare administrator from Singapore stopped by and said it plainly: "Everyone here is trying to sell me equipment I have to warehouse and maintain. You're showing me something I can deploy tomorrow on devices my patients already carry." That observation would repeat, in different forms, throughout the week.

The ASGH summit had attracted healthcare systems leaders, hospital CTOs, regional distributors, and investment firms from across Southeast Asia, India, and the Pacific. Many were frustrated with the gap between innovation announcements and real-world deployment speed. EYE TELL's smartphone-native approach—no hardware dependencies, no certification hurdles specific to devices—addressed a genuine pain point.

Live Demos and the Moment Things Became Real

Our demo strategy was straightforward: invite attendees to experience a scan in real time. Thirty seconds. A pupil analysis. Preliminary vital sign readings and risk indicators displayed instantly on the screen.

The reactions varied, but one pattern emerged. Initially, skepticism—"Can a smartphone camera really capture that level of detail?" Within 90 seconds of seeing their own data, curiosity shifted to clinical questions. "How does this perform in patients with cataracts?" "What's the sensitivity for early hypertension detection?" "Can your algorithm account for mydriatic medications?"

These weren't dismissive questions. They were the questions of healthcare professionals who understood that early detection only works if the tool is reliable enough to act on. Every question validated our positioning: we're not a wellness gimmick. We're a screening and early detection platform designed to catch risk signals before symptoms appear—and before they become costly interventions.

One moment crystallized the conference's potential. A senior cardiologist from Hong Kong—let's call him James—came through our booth on the second day. He scanned, reviewed the preliminary data, and paused. "This detected an irregular pattern in my pupil response," he said quietly. He was aware he'd been experiencing occasional palpitations but had dismissed them. He made an appointment with his own cardiologist that afternoon. Within a week, he had an ECG showing early atrial fibrillation. Early detection. Early intervention. The kind of story that justifies the entire mission.

"Everyone here is trying to sell me equipment I have to warehouse and maintain. You're showing me something I can deploy tomorrow on devices my patients already carry."

Building Bridges Across Asia's Healthcare Landscape

The real work of the summit, though, happened in the conversation spaces between sessions. We met with three regional organizations that became important partners:

These weren't casual conversations. Each organization came to the table with specific implementation questions: deployment timelines, regulatory pathways, integration with their existing workflows, pricing models for their markets. We left Hong Kong with memoranda of understanding and detailed project outlines with each.

What ASGH Revealed About the Market

Stepping back, the summit clarified something crucial about digital health adoption across Asia. Healthcare leaders aren't waiting for perfect solutions. They're looking for tools that address immediate gaps—specifically, the gap between when disease becomes clinically apparent and when it could have been detected and managed far earlier.

EYE TELL's value proposition at ASGH was singular: early detection, enabled by accessibility. A screening tool that works on infrastructure that already exists (smartphones) means health systems can begin identifying at-risk populations immediately. That data then enables the real action—referrals for confirmation, preventive interventions, lifestyle modifications, or early treatment. No waiting for hardware procurement cycles. No training specialists on proprietary systems.

The conference also reinforced something about our regulatory positioning. As we pursue FDA De Novo clearance, we're building toward a framework that Asia-Pacific regulators respect—rigorous evidence for screening and early detection capability, clarity about what we do not claim (treatment), and transparent performance data. ASGH attendees understood that distinction. Many are navigating their own regulatory pathways and value partners who are honest about scope.

Leaving Hong Kong With Momentum

We left the summit with three partnership pathways advancing, a database of 200+ engaged healthcare leaders, and most importantly, continued validation that the early detection problem we're solving is real, urgent, and geographically distributed across Asia. James's story—the incidental atrial fibrillation discovery—became part of how we'll describe EYE TELL's impact to future partners. Not as a treatment success, but as an example of how accessible screening can catch something that matters, when it still matters.

ASGH 2026 felt like a turning point. The market is ready. The partnerships are forming. The next phase is moving from summit conversations to deployed systems, scanning real patient populations, and building the evidence base that makes early detection actionable policy.